Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Thyroid2009Vol. 19(6), pp. 565–612
Citations Over TimeTop 1% of 2009 papers
Richard T. Kloos, Charis Eng, Douglas B. Evans, Gary L. Francis, Robert F. Gagel, Hossein Gharib, Jeffrey F. Moley, Furio Pacini, Matthew D. Ringel, Martin Schlumberger, Samuel A. Wells
Abstract
One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.
Related Papers
- → Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer(2011)24 cited
- → Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report(2018)10 cited
- → Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer(2012)1 cited
- Experience with vandeta nib in medullary thyroid cancer(2014)
- → Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)(2020)